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The inflammatory effects of TNF-α 
and complement component 3 on 
coagulation
Martin J. Page  1, Janette Bester2 & Etheresia Pretorius  1
Tissue necrosis factor-α (TNF-α) and complement component 3 (C3) are two well-known pro-
inflammatory molecules. When TNF-α is upregulated, it contributes to changes in coagulation and 
causes C3 induction. They both interact with receptors on platelets and erythrocytes (RBCs). Here, we 
look at the individual effects of C3 and TNF-α, by adding low levels of the molecules to whole blood 
and platelet poor plasma. We used thromboelastography, wide-field microscopy and scanning electron 
microscopy to study blood clot formation, as well as structural changes to RBCs and platelets. Clot 
formation was significantly different from the naïve sample for both the molecules. Furthermore, 
TNF-α exposure to whole blood resulted in platelet clumping and activation and we noted spontaneous 
plasma protein dense matted deposits. C3 exposure did not cause platelet aggregation, and only slight 
pseudopodia formation was noted. Therefore, although C3 presence has an important function to cause 
TNF-α release, it does not necessarily by itself cause platelet activation or RBC damage at these low 
concentrations. We conclude by suggesting that our laboratory results can be translated into clinical 
practice by incorporating C3 and TNF-α measurements into broad spectrum analysis assays, like 
multiplex technology, as a step closer to a patient-orientated, precision medicine approach.
Tissue necrosis factor-α (TNF-α) and complement component 3 (C3) are two well-known pro-inflammatory 
molecules1. They are not only upregulated in most inflammatory conditions, but their activities are closely linked. 
When TNF-α is upregulated, it contributes to changes in coagulation and C3 induction2. TNF-α plays a piv-
otal role in the disruption of macrovascular and microvascular circulation both in vivo and in vitro3,4, and is 
an important cytokine that can induce both apoptosis and inflammation5. In the presence of ROS, there is an 
increased production of TNF-α and, in turn, TNF-α signaling accentuates oxidative stress3. TNF-α upregulation 
is also associated with a changed coagulation propensity6,7. In short, TNF-α participates in vasodilatation and 
oedema formation, as well as leukocyte adhesion to the epithelium through expression of adhesion molecules. 
Furthermore, it regulates blood coagulation, contributes to oxidative stress at sites of inflammation, and indirectly 
induces fever6. TNF-α also plays a central role in the pathogenesis of insulin-resistant metabolic derangements.
C3 is a major protein of innate immunity and the complement system, with crucial roles in microbial killing, 
apoptotic cell clearance, immune complex handling and modulation of adaptive immune responses8. The rela-
tionship between upregulation of C3, inflammation, coagulation and hypofibrinolysis has been known for a long 
time9,10. Furthermore, pathology in the complement system is associated with an increased risk of pathological 
thrombotic processes11 e.g. stroke12 and in the pathogenesis of thromboembolism13.
C3 and TNF-α activity are interlinked, and examples of complement-dependent TNF release has been found 
in viral fulminant hepatitis2, atherosclerosis-induced inflammation14, rheumatoid arthritis15, human umbilical 
cord vein (HUVEC) endothelial cells16, and in insulin resistance17. It was also found that TNF-α synthesis by 
Mycobacterium avium is modulated through complement-dependent interaction via complement receptors 3 
and 4 in relation to M. avium glycopeptidolipid18. TNF-α may also induce epithelial to mesenchymal transition 
in injured renal tubular epithelial cells through inducing C3 expression19. Table 1 shows concentrations of both 
TNF-α and C3 in health and disease cited in the literature.
These two circulating pro-inflammatory molecules affect the coagulation and haematological system, as 
they interact with receptors on both platelets and erythrocytes (RBCs). Tumor necrosis factor receptors 1 and 2 
(TNFR1; TNFR2) are the primary TNF-α receptors20, with TNFR1, also known as tumor necrosis factor receptor 
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superfamily member 1A (TNFRSF1A) or CD120a, being the chief receptor. While RBCs do not express these 
receptors21, TNF can induce platelet consumption, and platelets do express TNFR1 and TNFR222,23. TNFR1 
expressed on other cells also causes the release of factors with agonist activity for platelets24; and TNF-α is able to 
activate platelets through stimulation of the arachidonic acid pathway22,23.
Turning to complement, RBCs carry the complement receptor 1 (CR1), also known as C3b/C4b receptor or 
CD35, on its membrane25. Immune complexes, which have reacted with complement and bear C3b fragments 
also bind to the CR1 on human RBCs, and CR1 on RBCs serves as a transport system for immune complexes in 
the circulation to prevent immune complex deposition outside the fixed macrophage system26–28. Complement 
also interacts with the surface of activated platelets as well as with other components of the complement system 
including, C1q, C4, C3, and C9, which bind to activated platelets11,29. Furthermore, thrombin-activated platelets 
can actually initiate the complement cascade29,30, and C3a and its derivative C3a-des-Arg, induce platelet acti-
vation and aggregation in vitro31. Platelets express complement receptors C3aR, CR4, as well as a receptor for 
iC3b and C5a, and the C1q receptors gC1qR and cC1qR on their membranes. cC1qR, in particular, was shown 
to mediate platelet aggregating and activating effects29. Of importance is that platelets may also interact with the 
complement system via proteins that are not considered classical complement receptors, such as P-selectin32 or 
GP1bα33.
In a series of papers, we have investigated the individual effects of inflammatory molecules on coagulation34,35. 
During inflammation, various circulating inflammatory molecules are upregulated, and a crucial result of this 
combination of molecules is a pathological haematological system that ultimately translates to hypercoagula-
tion, RBC dysfunction and platelet hyperactivation – all hallmarks of inflammation and cytokine upregulation. 
However, for clinical intervention, it is essential to know what the individual effects on these pro-inflammatory 
molecules are, to pinpoint possible biochemical interventions. Here we look at the individual effects of C3 and 
TNF-α, by adding low levels of the molecules to blood.
Materials and Methods
Ethical statement. The ethics committees of the University of Pretoria and Stellenbosch University (South 
Africa) approved this study (ethics clearance number 298/2016). A written form of informed consent was 
obtained from all healthy donors (available on request). The methods were carried out in accordance with the 
approved guidelines. Blood was collected and methods were carried out in accordance with the relevant guide-
lines of the ethics committee. We adhered strictly to the Declaration of Helsinki.
Sample and blood collection. Blood was collected from 14 healthy individuals who voluntarily enrolled 
for this study. Exclusion criteria for the healthy population were: known (chronic and acute) inflammatory 
conditions such as asthma, human immunodeficiency virus (HIV) or tuberculosis; risk factors associated with 
metabolic syndrome; smoking; and, if female, being on contraceptive or hormone replacement treatment. This 
population did not take any anti-inflammatory medication. Based on satisfying the exclusion criteria, the control 
donors were classified as ostensibly healthy. We therefore assumed that the TNF-α and C3 levels in our chosen 
sample population were in the ranges previously reported by researchers (see Table 1). Our added final concentra-
tions of the two products therefore slightly increased their intrinsic levels to simulate a state of low-grade chronic 
inflammation.
Blood was collected in citrate tubes and a plasma poor isolate was derived by centrifuging whole blood for 
15 minutes at 3000 g. Platelet poor plasma was stored at − 80 °C prior to experimentation.
Products: TNF-α and C3. We exposed whole blood and plasma separately to either TNF-α (Sigma T6674) 
or C3 (Sigma C2910) at levels that represent low-grade chronic inflammation. Our final TNF-α exposure 
Reference ranges for circulating C3 and TNF-α levels in humans
TNF-α levels in controls
5.6 ± 2.0 pg·ml−1 48
13.4 ± 0.81 pg·ml−1 in males and 13.9 ± 4.5 pg·ml−1 in females 4
14.80 ± 4.74 pg·ml−1 49
3.9 ± 2. 5 pg·ml−1 50
0.7 ± 0.2 pg·ml−1 51
TNF-α levels in disease
Type 2 diabetes: 4.28 ± 5.01 pg·mL−1 52
Chronic liver failure, TNF-α was found to be 
53.50 ± 73.49 pg·mL−1 amongst survivors
49
Metabolic syndrome: 6.3 ± 1.9 pg·ml−1 48
Aortic stenosis patients: 2.1 ± 1.6 pg·ml−1and mitral regurgitation: 
1.3 ± 0.7 pg·ml−1
51
C3 levels in controls
Healthy individuals 18 years and older: 88–201 mg·dL−1 53
88.5 ± 19 mg·dL−1 54
95 (94.5–95.5) mg·dL−1 55
C3 levels in disease
Prediabetes: 103.2 (102.5–03.8) mg·dL−1 55
Diabetes: 1.35 (1.10–1.60) g·L−1 56
Table 1. Circulating concentrations of TNF-α and C3 in health and disease.
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concentration in blood and plasma was 1 pg·mL−1 and our final C3 exposure concentration was 0.0025 mg·mL−1. 
We exposed blood to higher concentrations of TNF-α (15 and 30 pg·mL−1 final exposure concentration) and also 
to a higher final exposure concentration of 0.2 mg.mL−1 C3. These higher concentrations did not allow a clot to 
be formed on the TEG, as we could not obtain a clot R-time, suggesting that the added high concentrations were 
causing the clot to form too fast. However, we do believe that we simulated low-grade chronic inflammation with 
our low TNF-α and C3 final exposure concentration; but we do recognise that the physiological ranges during 
disease can be much higher.
Thromboelastography of whole blood and platelet poor plasma. Viscoelastic assessment of clot 
kinetics was performed using thromboelastography (TEG). Whole blood (WB) and platelet poor plasma (PPP) 
from healthy donors was incubated with TNF-α or C3 for 10 minutes prior to assessment. WB was left at room tem-
perature for 15 minutes following collection before being incubated. PPP was first thawed to room temperature from 
storage at −80 °C before incubation. 340 μL of naïve (untreated) or product-exposed WB or PPP was mixed with 
20 μl of 0.2 M CaCl2 in a disposable TEG cup. Recalcification of blood is necessary to reverse the effect of the sodium 
citrate collecting tube anticoagulation method and consequently initiate coagulation. The samples were then placed 
in the computer-controlled Thromboelastograph® 5000 Hemostasis Analyzer System (Haemonetics Inc., Braintree, 
MA, USA) for analysis at 37 °C. Table 2 summarises the seven clot parameters that were studied36–38.
Wide-field microscopy of whole blood using the Zeiss CellDiscoverer 7. RBC autofluorescence 
was used to follow the effects of the products added to WB. Images were acquired with the Zeiss CellDiscoverer 
7 using a combination of three LED modules simultaneously: 385, 470 and 567 nm wavelengths. The following 
bandpass emission filters were used: 412–438; 501–527 and 583–601. A Plan-Apochromat 50×/1.2NA objective 
with a 2× tube lens and an Axiocam 506 mono-camera were used for image acquisition. The live cell imaging 
procedure included adding 99 μL of WB in a plate and imaging the naïve sample. Then, 1 μL of either TNF-α or 
C3 was added, and following stabilisation of the sample, images were captured at 3 minutes after exposure.
Scanning electron microcopy of whole blood. Blood smears were prepared for SEM analysis using 
WB after exposure to TNF-α and C3 for 10 minutes. In short, 10 μL of unexposed naïve and product-exposed 
WB were placed on glass cover slips and smears were washed in PBS, fixed in 4% formaldehyde and 1% osmium 
tetraoxide before being dehydrated in increasing grades of ethanol and HMDS (for detailed methods see34,38). 
Micrographs of WB smears were taken using a Zeiss crossbeam electron microscope and Merlin (Gemini II) 
FE SEM to study the ultrastructure of the both platelets and RBCs, with specific focus on their membranes. 
Image acquisition was performed independently at both the Universities of Stellenbosch and Pretoria. The images 
acquired at both these institutions are stored as raw data (see link below).
Statistical analysis. TEG parameters were analysed by the repeat measures One-Way ANOVA with the 
Holm-Sidak test (and this includes corrections such as the Greenhouse-Geisser correction for sphericity/equal 
variability of differences). This type of analysis allows us to compare each product exposure with the control 
(GraphPad Prism 7), with statistical significance taken as p ≤ 0.05.
Data sharing. Raw data, extensive SOPs for TEG and SEM, including original images without color and 
micrographs can be accessed at: https://1drv.ms/f/s!AgoCOmY3bkKHuh5Av5hYQU5UQgdG. Raw data 
can also be access at the corresponding author’s researchgate link: https://www.researchgate.net/profile/
Etheresia_Pretorius.
Results
Thromboelastography of whole blood and platelet poor plasma. WB TEG parameters reflect clot 
properties due to both the cellular components (viz. platelets and RBC), as well as the plasma protein compo-
nents38; while PPP clot results reflect only the effect of the plasma proteins, chiefly fibrin(ogen). Table 3 shows 
sample demographics and TEG results for both WB and PPP, with significant p-values in bold.
Parameters Explanation
R value: reaction time; measured in minutes Time of latency from start of test to initial fibrin formation (amplitude of 2 mm); i.e. initiation time
K value: kinetics; measured in minutes Time taken to achieve a certain level of clot strength (amplitude of 20 mm); i.e. amplification
Angle (Α/Alpha): slope between the traces 
represented by R and K; measured in degrees
The angle measures the speed at which fibrin build up and cross linking takes place, hence 
assesses the rate of clot formation; i.e. thrombin burst
Maximal Amplitude (MA): measured in mm Maximum strength/stiffness of clot. Reflects the ultimate strength of the fibrin clot, i.e. overall stability of the clot
Maximum rate of thrombus generation 
(MRTG): measured in Dyn.cm−2.s−1
The maximum velocity of clot growth observed or maximum rate of thrombus generation 
using G, where G is the elastic modulus strength of the thrombus in dynes per cm−2
Time to maximum rate of thrombus 
generation (TMRTG): measured in minutes The time interval observed before the maximum speed of the clot growth
Total thrombus generation (TTG): measured 
in Dyn.cm−2
The clot strength: the amount of total resistance (to movement of the cup and pin) generated 
during clot formation. This is the total area under the velocity curve during clot growth, 
representing the amount of clot strength generated during clot growth
Table 2. TEG clot parameters for whole blood and platelet poor plasma (adapted from38).
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Demographic Data of Healthy Individuals N = 14; Age 24.0 ± 12.2; M = 57%; F = 43%
TEG results for naïve whole blood exposed to TNF-α or C3 for 10 minutes at room temperature
Naïve (n = 8) TNF-α (n = 8) Naïve vs TNF-α P-value Complement 3 (n = 8) Naïve vs C3 P-value
R 9.30 ± 1.47 8.40 ± 1.09 0.077 8.85 ± 0.93 <0.0001
K 3.80 ± 0.95 3.45 ± 1.02 0.16 3.55 ± 1.04 0.24
Angle 45.10 ± 5.37 48.50 ± 7.57 0.16 47.20 ± 7.66 0.16
MA 52.25 ± 5.43 54.35 ± 8.03 0.96 53.30 ± 5.32 0.76
MRTG 3.35 ± 0.79 3.82 ± 1.03 0.17 3.89 ± 1.06 0.17
TMRTG 13.84 ± 3.49 12.54 ± 3.66 0.37 13.17 ± 2.46 0.45
TTG 547.03 ± 141.48 596.87 ± 150.22 0.86 594.38 ± 127.38 0.77
TEG results for naïve platelet poor plasma exposed to TNF-α or C3 for 10 minutes at room temperature
Naïve (n = 11) TNF-α (n = 11) Naïve vs TNF-α P-value Complement 3 (n = 11) Naïve vs C3 P-value
R 13.20 ± 3.31 11.80 ± 1.97 0.03 10.60 ± 2.58 0.03
K 4.50 ± 2.31 4.60 ± 1.31 0.60 4.80 ± 2.17 0.94
Angle 43.60 ± 13.73 47.80 ± 8.55 0.11 52.00 ± 10.00 0.12
MA 23.80 ± 5.51 24.60 ± 4.92 0.99 22.90 ± 6.32 0.91
MRTG 3.11 ± 1.35 3.16 ± 1.62 0.05 3.41 ± 1.75 0.03
TMRTG 13.92 ± 3.51 13.33 ± 2.33 0.02 11.83 ± 3.18 0.13
TTG 155.64 ± 56.98 164.16 ± 54.24 0.83 148.62 ± 64.15 0.83
Table 3. Sample demographics and TEG results for both WB and PPP before and after exposure to TNF-α or 
C3. Values presented as median ± standard deviation.
Figure 1. Wide-field microscopy using the Zeiss CellDiscoverer 7, before and 3 minutes after exposure to 
TNF-α or C3.
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Wide-field microscopy using the Zeiss CellDiscoverer 7. Figure 1 shows the wide-filed microscopy 
results before and after exposure to TNF-α and C3. This equipment gives us the option to, in real-time, observe 
changes as the inflammatory molecules are added. We could not detect any changes to RBCs after exposure to 
the low physiological concentrations of the products. We followed up this experiment with scanning electron 
microscopy, where we could look at cellular interactions between platelets and RBCs and at membrane changes 
in these cells, using high magnification.
Scanning electron microscopy of whole blood. Figure 2A shows a typical healthy whole blood smear, 
at low magnification, and Fig. 2B and C, higher magnification of RBCs and platelets. Figure 3 shows micrographs 
from healthy whole blood exposed to TNF-α and C3. TNF-α exposure resulted in both RBC damage and plate-
let hyeractivation and clumping, while C3 exposure only resulted in a slightly increased platelet pseudopodia 
formation.
Discussion
During inflammation, various circulating inflammatory molecules are upregulated, and a crucial result of this 
combination of molecules is a pathological haematological system that ultimately translates to hypercoagula-
tion, RBC dysfunction and platelet hyperactivation – all hallmarks of inflammation and cytokine upregulation. 
However, for clinical intervention, it is essential to know what the individual effects on these pro-inflammatory 
molecules are, to pinpoint possible biochemical interventions. Here we look at the individual effects of C3 and 
TNF-α, by adding low levels of the molecules to blood. In a series of papers, we have investigated the individual 
effects of inflammatory molecules on coagulation34,35.
In our previous research we noted that the presence of all inflammatory molecules such as IL-1ß, IL-6, Il 8 and 
Il-12 cause platelets to be hyperactivated, clumped or aggregated34,35,39. In the current investigation, only TNF-α 
exposure, resulted in platelet clumping and activation (See Fig. 3A). TNF-α exposure also resulted in spontaneous 
plasma protein dense matted deposits, that surrounded and covered RBCs and showed interactions with platelet 
pseudopodia (Fig. 3B and C). C3, at the physiological levels that we used, did not cause platelet aggregation, and 
only slight pseudopodia formation was noted. This is an important observation, as C3 and TNF-α activity are 
Figure 2. (A) Low magnification of a healthy whole blood smear prepared for scanning electron microscopy. 
(B) A representative RBC and (C) a representative platelet. (D) RBCs and platelet showing little activation.
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interlinked, and examples of complement-dependent TNF-α release are well-known, as discussed in the intro-
duction. Therefore, although C3 presence has an important function to cause TNF-α release, it does not neces-
sarily by itself cause platelet activation.
Increased levels of TNF-α are known to activate platelets40,41, and during inflammation, complement is 
activated on the surface of platelets, despite the presence of multiple regulators of complement activation11. A 
recent paper also showed that C3 plays specific roles in platelet activation42. The authors showed, in a tissue 
factor-dependent model of flow restriction-induced venous thrombosis, that complement factors play a role in 
Figure 3. (A to D) Healthy whole blood smear after exposure to TNF-α and then prepared for scanning 
electron microscopy. (E to H) Healthy whole blood exposed to complement component 3.
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platelet activation and fibrin deposition42. In our paper, we did not additionally quantitatively assess platelet acti-
vation in the presence of our chosen molecules, but showed the effect visually using SEM.
We have also previously shown that RBCs may be affected by cytokines and that they can become eryptotic 
in the presence of cytokines like IL-834 or agglutinated in the presence of IL-1239. In the current investigation, we 
did not observe any eryptosis, however, TNF-α did cause membrane changes and this was visible as membrane 
disintegration (see Fig. 3D). This was, however, not present in the majority of the cells. C3 did not cause any 
structural membrane changes after exposure. The results were confirmed with the wide-field microscopy results.
SEM allows the visualization of samples at a very detailed resolution. With TNF-α exposure, the RBC mor-
phology did not appear to be the primary change. Rather, the plasma proteins appeared be changed and covered 
some of the RBCs. Also, with SEM we noted greater platelet reactivity. Since the wide-field visualization was based 
only on RBC auto-florescence and that it is not as sensitive as SEM, these changes were also not readily apparent 
with this technique.
Our TEG results showed that there were no significant differences in naïve whole blood when compared with 
whole blood samples with added TNF-α; although the R-time showed a trend towards a faster clotting initiation 
time (p = 0.077). When C3 was added to whole blood, the R-time shorted significantly. Overall these two prod-
ucts seem to promote a faster clot initiation. There were significant differences in the TEG results when platelet 
poor plasma (PPP) was analysed. It is known that the diagnosis of hypercoagulability are based on changes in 
variables of hemostatic monitors such as a decrease in the time to clot initiation (reaction time, R), an increase in 
the speed of clot propagation (angle), or an increase in clot strength (amplitude, A; or shear elastic modulus G). 
This indicates an enhancement of hemostasis or hypercoagulability as defined with TEG43,44. Here we show a sig-
nificant decrease in the R-time, MRTG and the TMRTG with PPP and added TNF-α. Also a significant decrease 
in R-time and a significant increase in MRTG with PPP and added C3. According to the results, the PPP samples 
with the added C3 and TNF-α showed that more parameters point towards hypercoagulation, thus suggesting 
these molecules have a more profound effect on fibrin formation.
Defining and understanding the role of cytokines and other inflammatory mediators, like TNF-α and C3 in 
(inflammatory) diseases, is becoming increasingly important, especially in patient-orientated and precision-based 
therapy initiatives45. We conclude by suggesting that our laboratory results can be translated into clinical practice 
by incorporating C3 and TNF-α measurements into broad spectrum analysis assays, like multiplex technology, 
that measures various cytokines (e.g. interleukins). Developments in inflammatory marker quantification tech-
nology, like multiplex assays and arrays, allow for an improved evaluation and understanding of the dynamic 
nature of inflammatory responses46,47. Furthermore, multiplexed protein array assays provide high sensitivity and 
specificity using low sample volumes in a high throughput analysis and, in addition, can be used during therapeu-
tic drug monitoring. With such approaches, therapy outcomes can also be followed with more accuracy, and in 
the long run, reduce treatment costs, as well as expedite wellness outcomes.
Considering that our results show that these two molecules have a pro-coagulant effect on blood, in addition 
to a place in diagnostics, it might be of importance to evaluate further the biochemical mechanisms by which 
C3 and TNF-α modulate pro-coagulant pathways. This might reveal a therapeutic potential for lowering the 
pro-coagulant state due to C3 and TNF-α, present in inflammatory diseases.
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